Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 89215
- Registration Number
- NCT05083455
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- André Luiz Malavasi Longo de Oliveira
- Target Recruit Count
- 440
- Registration Number
- NCT04999176
- Locations
- 🇧🇷
Science Valley Research Institute, Santo André, São Paulo, Brazil
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 258
- Registration Number
- NCT04924322
- Locations
- 🇺🇸
Maria Fareri Children's Hospital, Valhalla, New York, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 12
- Registration Number
- NCT04861103
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT04736901
- Locations
- 🇪🇬
Teachers Hospital, Cairo, Please Select, Egypt
Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- ASST Fatebenefratelli Sacco
- Target Recruit Count
- 142
- Registration Number
- NCT04646655
- Locations
- 🇮🇹
ASST Fatebenefratelli Sacco, Milan, Italy
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- St. David's HealthCare
- Target Recruit Count
- 150
- Registration Number
- NCT04640181
- Locations
- 🇺🇸
St. David's Medical Center, Austin, Texas, United States
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04558125
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2023-01-30
- Target Recruit Count
- 65
- Registration Number
- NCT04558892
- Locations
- 🇵🇱
Military Institute of Medicine, Warsaw, Masovian District, Poland
Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 172
- Registration Number
- NCT04552067
- Locations
- 🇹🇳
Emergency Department of University Hospital of Monastir, Monastir, Tunisia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.